leadf
logo-loader
view4D pharma PLC
(
AIM:DDDDNASDAQ:LBPS
)

4d pharma says Merck KGaA and Pfizer cancer collaboration is 'big step forward'

4D pharma PLC's (LON:DDDD) chief executive Duncan Peyton talks to Proactive London's Katie Pilbeam about the clinical trial collaboration and supply agreement with Merck KGaA, and Pfizer Inc.

Peyton says 'it's another step forward in how we work and expand our oncology franchise' which will begin with a clinical trial this year with BAVENCIO. 

This is a drug for advanced or metastatic urothelial carcinoma (a form of bladder cancer) developed by Merck and Pfizer, in combination with UK group’s MRx0518.

Quick facts: 4D pharma PLC

Follow
AIM:DDDD

Price: 64 GBX

Market Cap: £115.39 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

FTSE rides on wave of results and reopening optimism boosts the market mood

FTSE 100 rose as a wave of results and reopening optimism boosted the mood on investors. Anglo American and Shell were good, BT not so much and the blue-chip index was up 45 at points at 7,061. Lloyds Banking Group (LSE:LLOY) PLC declared its first interim dividend after the recent removal of...

on 29/7/21

2 min read